Date: 2016-12-16
Type of information: Collaboration agreement
Compound: intellectual property for CRISPR/Cas9 gene editing technology
Company: CRISPR Therapeutics (Switzerland - USA - MA) Intellia Therapeutics (USA - MA) Caribou Biosciences (USA - CA) ERS Genomics (Ireland)
Therapeutic area: Technology - Services
Type agreement: collaboration
Action mechanism:
Disease:
Details: • On December 16, 2016, Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology. The parties to the agreement include the co-owners of the intellectual property – the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna – as well as key licensees and sublicensees – CRISPR Therapeutics, ERS Genomics, Caribou Biosciences, and Intellia Therapeutics. Under the agreement, the parties commit to maintain and coordinate the prosecution, defense and enforcement of the CRISPR/Cas9 foundational patent portfolio worldwide, and each of the co-owners of the intellectual property grants cross-consents to all existing and future licenses and sublicenses based on the rights of another co-owner.
Financial terms:
Latest news:
